CD274 and head and neck squamous cell carcinoma: The introduction of immunotherapy for patients with head and neck squamous cell carcinoma (HNSCC) raises the need for harmonisation between different types of antibody and immunohistochemistry platform for evaluating the expression of PD‐L1 by use of the combined positive score (CPS) in this tumour.